Language

English

Publication Date

4-14-2026

Journal

Nature Communications

DOI

10.1038/s41467-026-71967-y

PMID

41980961

PMCID

PMC13254347

PubMedCentral® Posted Date

4-14-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Proteome and transcriptome data combined can help assess the relevance of non-coding germline variants. Here, we combine germline Structural Variants (SVs) with mass spectrometry-based proteomics on tumors from 1637 cancer patients spanning various tumor tissues of origin to determine the extent SV breakpoint patterns involve differential protein expression of nearby genes. Rare and singleton SVs disrupting protein expression of known cancer susceptibility genes collectively involve 6% of patients. About 24% of the hundreds of genes with SV-associated non-coding cis-regulatory alterations at the mRNA level are similarly associated at the protein level. Both rare and common SVs may associate with differential protein expression within a specific tumor type or across multiple tissue types, including SVs differentially represented by patient ancestry. SVs involving altered methylation of CpG Islands or enhancers are also implicated in differential protein expression. Our results emphasize the contribution of germline SVs to cancer heterogeneity at the proteome level.

Keywords

Humans, Proteome, Neoplasms, Germ-Line Mutation, Proteomics, CpG Islands, DNA Methylation, Gene Expression Regulation, Neoplastic, Mass Spectrometry, Genetic Predisposition to Disease, Germ Cells, Transcriptome, Cancer genomics, Cancer epigenetics, Protein analysis, Mass spectrometry, Gene expression

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.